Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that distinct alopecia scoring systems measure percent hair loss as a common underlying feature, with strong correlations observed between different types of hair loss assessments.

In this study, a combination of low-dose minoxidil 0.25 mg and spironolactone 25 mg reduced hair shedding and improved hair density in patients with female pattern hair loss, with mild adverse effects.

This article discusses hair shedding in women and does not offer new research results; it highlights the need for objective criteria to define excessive hair shedding.

Low-dose Minoxidil combined with Spironolactone helps reduce hair loss and improve hair density in women, with some mild side effects.

This review discusses various dermatological scoring systems used to objectively assess disease severity and guide treatment decisions, reporting no new clinical results.

In this retrospective analysis, patients with trichodynia who were unresponsive to standard treatments showed significant symptom improvement after receiving intradermal botulinum toxin type A, with nearly all patients benefiting, particularly those with scarring alopecia.

This study established and validated a visual scale to assess hair shedding in women with thick hair, finding it effective in distinguishing greater hair loss among women with female pattern hair loss compared to those without.

This correspondence reports that some men with androgenetic alopecia can exhibit hair thinning patterns more typical of females, with variations observed between Australian and Korean populations.

In this interventional study, researchers found that combining tretinoin cream with microdermabrasion significantly improved hair regrowth and satisfaction in alopecia areata patients compared to tretinoin alone, with notable benefits observed over eight weeks.

This review found that oral and topical phosphodiesterase inhibitors and topical prostaglandin analogues are safe and effective treatments for various skin diseases, including psoriasis, atopic dermatitis, vitiligo, and alopecia.

This review discusses female pattern hair loss, highlighting that while oral antiandrogens and topical minoxidil can arrest progression, early diagnosis and treatment are crucial, and stresses the need for ongoing therapy.

This study assessed the use of oral finasteride in transgender men with androgenetic alopecia and found that all patients improved by one grade on the Norwood–Hamilton scale within about 5.5 months, with no significant adverse effects reported during the 16.2 months of follow-up.

This review found evidence supporting the effectiveness and safety of topical minoxidil for treating female pattern hair loss, though many included studies were at high risk of bias.

In this study of 36 women with chronic telogen effluvium, once daily oral minoxidil significantly reduced hair shedding over 12 months, though some participants experienced facial hypertrichosis and other mild side effects. The authors concluded that placebo-controlled studies are needed to confirm these results.

Oral minoxidil effectively reduces hair shedding in women with chronic telogen effluvium.

This review discusses the clinical efficacy, safety, and mechanisms of Autologous Micrografting Technology for androgenetic alopecia, reporting significant short-term improvements in hair density and thickness.

This study found that 88% of women with female pattern hair loss who received oral antiandrogens saw no progression or improvement in their condition.

This study observed that triple horizontal scalp biopsies provided a more accurate diagnosis of female pattern hair loss in women than a single horizontal biopsy, especially for those with advanced hair loss.

This review discusses the characteristics and management options for female pattern hair loss, highlighting the unclear role of androgens and the psychosocial impact, and reports no new clinical results.

This study reported that once-daily treatment with oral minoxidil and spironolactone for 12 months reduced hair loss severity and hair shedding in women with pattern hair loss, with generally mild side effects, though results came from an uncontrolled, observational pilot study.

This review suggests that oral prednisolone pulse therapy and oral inosiplex may be effective for alopecia areata, but robust evidence from randomized controlled trials is lacking, highlighting the need for better-designed future studies.

In this study, women with chronic telogen effluvium experienced reduced hair shedding after being treated with once daily oral minoxidil for 12 months, but facial hypertrichosis was a reported side effect, suggesting the need for further placebo-controlled research.

Male pattern hair loss could hint at androgens affecting COVID-19 severity.

This study found that adjuvant docetaxel chemotherapy is linked to higher rates of dissatisfaction and chronic alopecia compared to paclitaxel chemotherapy, suggesting these outcomes should be discussed with patients before using docetaxel regimens.

The document suggests a bacteria plays a significant role in acne rosacea and that white hair can regain color after transplant, meriting more research on reversing grey hair.

In this study, PRP injections were found to improve hair density and quality in patients with androgenetic alopecia, with a significant reduction in hair loss and high patient satisfaction after three treatment sessions over several months.

This study found that younger, unmarried individuals under 40, especially women, experienced significant anxiety and depression due to androgenetic alopecia, impacting their psychological well-being and self-perception.

This review reports that the treatment of androgenetic alopecia is shifting from single therapies to personalized, multimodal approaches incorporating both traditional and emerging pharmacologics, regenerative strategies, nutraceuticals, cosmeceuticals, and device-based interventions, with combination regimens showing improved outcomes.

This study found that patients with alopecia areata experience significant impairments in health-related quality of life, notably affecting mental health, according to various quality of life assessment tools.

Various treatments exist for hair loss, but more research is needed for better options.